LamassuBiotech
  • Company
    • Mission & History
    • Leadership & Key Collaborators
    • Partners
  • The Lamassu Method
  • Pipeline
    • SA53
    • RABI-767
  • Lamassu Pets
  • Investor Resources
    • Investor Resources
    • Events & Presentations
  • News
    • News Releases
    • Media Coverage
  • Contact Us
  • EN
  • FR

Tag: Cleveland

05/16/2025

LAMASSU BIOTECH COLLABORATES WITH THE OHIO STATE UNIVERSITY TO STUDY NEW THERAPY FOR MAN AND MAN’S BEST FRIEND

Pioneering Research Will Help Drive Dual-Purpose Treatment for Life-Threatening Conditions in Both Humans and Man’s Best Friend (CLEVELAND, OH) – Man’s best friend may soon benefit from a new treatment,...
READ THE ARTICLE
11/05/2024

Cleveland.com: Biotech startup Lamassu, Cleveland Clinic aim to treat rare cancers with just three pills a month

CLEVELAND, Ohio — A biotech startup from North Carolina thinks Cleveland is where it will develop how to treat rare cancers with just three pills a month. If effective, Lamassu Biotech’s innovative...
READ THE ARTICLE

Recent Posts

  • Crain’s Cleveland Business: Cleveland biotech company secures $2.7M in NIH funding
  • Cleveland Business Journal: Lamassu Biotech’s dog treatment could lead to human pancreatitis breakthrough, backed by NIH funds
  • SIGNIFICANT NIH GRANT WILL HELP LAMASSU BIOTECH ADVANCE LIFE-SAVING PANCREATITIS TREATMENT FOR DOGS
  • LAMASSU BIOTECH COLLABORATES WITH THE OHIO STATE UNIVERSITY TO STUDY NEW THERAPY FOR MAN AND MAN’S BEST FRIEND
  • The Washington Times: Biotech should take a page from Elon Musk’s playbookThe Washington Post:

Recent Comments

No comments to show.

Archives

  • June 2025
  • May 2025
  • April 2025
  • February 2025
  • November 2024
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • April 2021
  • August 2020
  • March 2020

Categories

  • media
  • news
  • Uncategorized

Menu

  • Investor Resources
  • News Releases
  • Contact us

Questions?

1-919-246-3969

info@lamassubio.com

  • Privacy Statement
  • Terms Of Use
  • Accessibility
  • FCOI Policies